Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Castle Creek Biosciences, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Phase 3

Recruiting

Conditions: Dystrophic Epidermolysis Bullosa

Interventions: Biological: D-Fi

First Posted Date: 2025-03-25

Last Posted Date: 2025-06-11

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 32

Registration Number: NCT06892639

Locations: 🇺🇸
Thomas Jefferson University Dept of Dermatology and Cutaneous Biology, Philadelphia, Pennsylvania, United States
🇺🇸
Stanford University School of Medicine, Dermatology, Redwood City, California, United States
🇺🇸
Mission Dermatology, Santa Margarita, California, United States

and more 2 locations

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Phase 3

Active, not recruiting

Conditions: Recessive Dystrophic Epidermolysis Bullosa

Interventions: Biological: FCX-007 (dabocemagene autoficel; see below for FCX-007 description)

First Posted Date: 2019-12-30

Last Posted Date: 2024-04-01

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 6

Registration Number: NCT04213261

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Dell Children's Medical Group, Austin, Texas, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 2 locations

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Phase 1

Terminated

Conditions: Scleroderma
Morphea
Scleroderma, Localized

Interventions: Genetic: FCX-013
Drug: veledimex

First Posted Date: 2018-11-14

Last Posted Date: 2024-01-23

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 1

Registration Number: NCT03740724

Locations: 🇺🇸
Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase 1

Terminated

Conditions: Epidermolysis Bullosa Dystrophica, Recessive

Interventions: Genetic: FCX-007

First Posted Date: 2016-06-23

Last Posted Date: 2023-02-08

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 6

Registration Number: NCT02810951

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

Phase 2

Completed

Conditions: Age-related Dysphonia
Dysphonia Resulting From Vocal Fold Scarring

Interventions: Drug: Placebo
Biological: Azficel-T (autologous fibroblasts)

First Posted Date: 2014-04-23

Last Posted Date: 2021-06-03

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 21

Registration Number: NCT02120781

Locations: 🇺🇸
Dept of Otolaryngology, Stanford Univ Medical Center, Stanford, California, United States
🇺🇸
Surgery/Head and Neck, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
NYU Langone Medical Center, New York, New York, United States

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

Phase 2

Terminated

Conditions: Restrictive Burn Scars

Interventions: Biological: Autologous fibroblasts
Biological: placebo sterile saline

First Posted Date: 2013-05-21

Last Posted Date: 2021-10-13

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 5

Registration Number: NCT01858753

Locations: 🇺🇸
Richard M. Fairbanks Burn Center, Indianapolis, Indiana, United States
🇺🇸
Center for Innovation in Restorative Medicine, Pittsburgh, Pennsylvania, United States
🇺🇸
Division of Burns and Trauma, Jackson Memorial Hospital, Miami, Florida, United States

and more 6 locations

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

Phase 2

Completed

Conditions: Interdental Papillary Insufficiency

Interventions: Biological: Autologous Human Fibroblasts (azficel-T)

First Posted Date: 2008-04-10

Last Posted Date: 2021-03-23

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 13

Registration Number: NCT00655889

Locations: 🇺🇸
Perio-Health Professionals, Inc., Houston, Texas, United States

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases

Phase 2

Completed

Conditions: Facial Wrinkles and Creases

Interventions: Biological: Autologous Human Fibroblasts (azficel-T)

First Posted Date: 2008-04-09

Last Posted Date: 2012-03-13

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 50

Registration Number: NCT00654654

Locations: 🇺🇸
The Laser Institute for Dermatology, Santa Monica, California, United States
🇺🇸
Rhonda Rand, M.D., Inc., Beverly Hills, California, United States
🇺🇸
Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte, North Carolina, United States

and more 2 locations

Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

Phase 3

Completed

Conditions: Bilateral Nasolabial Fold Wrinkles

Interventions: Biological: Autologous Human Fibroblasts (azficel-T)
Biological: Placebo

First Posted Date: 2008-04-09

Last Posted Date: 2012-03-13

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 218

Registration Number: NCT00655356

Locations: 🇺🇸
Brighton Medical Corporation, Beverly Hills, California, United States
🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸
Charlottesville Medical Research, Charlottesville, Virginia, United States

and more 3 locations

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

Phase 3

Completed

Conditions: Bilateral Nasolabial Fold Wrinkles

Interventions: Biological: Placebo
Biological: Autologous Human Fibroblast (azficel-T)

First Posted Date: 2008-04-01

Last Posted Date: 2012-03-13

Lead Sponsor: Castle Creek Biosciences, LLC.

Target Recruit Count: 203

Registration Number: NCT00649428

Locations: 🇺🇸
Silverburg Surgical & Medical Group, Newport Beach, California, United States
🇺🇸
Dermatology Research Institute, LLC, Coral Gables, Florida, United States
🇺🇸
Total Skin & Beauty Dermatology Center, PC, Birmingham, Alabama, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy